Compare DOGZ & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DOGZ | IXHL |
|---|---|---|
| Founded | 2003 | 2001 |
| Country | China | Australia |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.5M | 97.6M |
| IPO Year | 2017 | 2024 |
| Metric | DOGZ | IXHL |
|---|---|---|
| Price | $1.54 | $3.98 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 387.0K | ★ 5.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.02 | $0.11 |
| 52 Week High | $34.53 | $5.17 |
| Indicator | DOGZ | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 24.47 | 86.14 |
| Support Level | $1.02 | $0.32 |
| Resistance Level | $1.71 | N/A |
| Average True Range (ATR) | 0.15 | 0.20 |
| MACD | 0.34 | 0.45 |
| Stochastic Oscillator | 59.09 | 75.88 |
Dogness (International) Corp designs, manufactures pet products, including leashes and smart products, and lanyards. The company designs, processes, and manufactures fashionable and high-quality leashes, collars, and harnesses to complement cats' and dogs' appearances, as well as intelligent pet products. The company also provides dyeing services to external customers, as well as pet grooming services. The dyeing service is to utilize the existing production capacity and the pet grooming service is immaterial. Geographically, it generates maximum revenue from Mainland China and also has a presence in the United States, Europe, Australia, Canada, Central, and South America, Japan, and other Asian countries and regions.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.